Funding led by Eos Advisory and Midlands Engine Investment Fund II, through appointed fund  manager Mercia Ventures, signals strong investor confidence despite challenging market conditions. 

Neupulse, a neurotherapeutics company focused on  delivering innovative solutions to people with brain health conditions, like Tourette Syndrome, has announced  it has successfully raised £3 million in new funding. 

The round was led by Eos Advisory and the Midlands Engine Investment Fund II, through appointed fund  manager Mercia Ventures, with participation from existing and new investors. 

The funding will be used to scale sales and accelerate Neupulse’s path to market, supporting product  development, regulatory progress and early commercialisation, to ensure the company’s technology reaches  individuals who need it most. 

The funding comes at a time when venture and growth funding remains highly constrained, underscoring  the strength of Neupulse’s proposition and the confidence investors have in both the company’s mission and  execution. Neupulse’s continued momentum highlights growing demand for effective, clinically grounded  neurotherapeutic solutions and positions Neupulse strongly for its next phase of growth. 

Neupulse’s product is designed to address critical gaps in current treatment options, combining scientific  rigour with a clear focus on real-world impact. This funding round enables the company to move decisively  from development towards commercial launch in mid-2026, while continuing to build the evidence base  required by clinicians, regulators, and healthcare systems. 

The company first secured funding from the Midlands Engine Investment Fund II in 2024 to finalise  development of a non-drug treatment to help manage the symptoms of Tourette’s Syndrome. The £500,000  investment helped Neupulse’s continued research into the TS therapy wristband device and clinical trials.    

Eos and Mercia Ventures are both experienced backers of high-growth healthcare and deep-tech businesses,  bringing not only capital but strategic expertise to support Neupulse. Their continued leadership reflects a  shared belief in the company’s long-term potential and its ability to generate both commercial and clinical  value. 

Paul Cable, CEO, Neupulse said: “This investment underlines the unmet need in providing people with  conditions like Tourette Syndrome a solution to manage their condition, and as a company, we are driven to  improve the lives of individuals with these conditions.” Ian Rhodes, Chair of the board at Neupulse, added: “This is a great example of advanced biomedical  research from a leading UK university creating an initial UK market launch during 2026. This will increasingly  benefit the UK economy as the technology scales out globally.” 

David Tindall, Senior Investment Manager at the British Business Bank, said: “Neupulse’s growth  over the past year, following investment from the Midlands Engine Investment Fund II, has been impressive.  By addressing a clear gap in the market and delivering a much-needed solution for those affected, the  business exemplifies the Fund’s commitment to backing ambitious, high-growth companies. This latest round  of funding will further support Neupulse in developing and launching new treatment options.” 

Andrew McNeill, Investor Director at Eos, said: "We are delighted to support the next chapter of  Neupulse as they move towards commercialisation. This is exactly the kind of company and science we like  to back. Passionate founders and technology with the potential to positively impact the lives of people across  the globe.” 

Sandy Reid, Fund Principal, Mercia Ventures added: “Tourette Syndrome is believed to affect up to two  per cent of all children worldwide but currently the only treatments are medication and behavioural therapy,  neither of which are ideal solutions. Neupulse’s device offers a genuine alternative that could transform lives.” 

The £400m Midlands Engine Investment Fund II covers the entire Midlands region and provides debt finance  from £25k to £2m and equity investment up to £5m to help a range of small and medium sized businesses  to start up, scale up or stay ahead. The purpose of the Midlands Engine Investment Fund II is to drive  sustainable economic growth by supporting innovation and creating local opportunity for new and growing  businesses across the Midlands. The Midlands Engine Investment Fund II will increase the supply and  diversity of early-stage finance for smaller businesses in the Midlands, providing funds to firms that might  otherwise not receive investment and help to break down barriers in access to finance.